1%

Question 1 of 30

You are treating a patient with localized osteosarcoma of the distal femur with methotrexate, doxorubicin, and cisplatin (MAP) chemotherapy. At week 10 of treatment, the patient undergoes complete resection of the tumor. Pathology demonstrates 40% necrosis. Which of the following represents the most appropriate further therapy?

Rationale:
D: MAP. Continuing with MAP therapy is essential after observing 40% necrosis, as it indicates a partial response to initial chemotherapy and helps consolidate treatment to improve long-term outcomes. A: Ifosfamide and etoposide (IE) does not align with the patient's current regimen and lacks the synergistic benefit of combining with the already effective MAP treatment. B: MAP plus ifosfamide and etoposide (MAPIE) introduces unnecessary complexity without proven superiority, potentially increasing toxicity and complicating treatment without clear additional benefit from the combined regimen. C: Gemcitabine docetaxel fails to leverage the patient's prior chemotherapy response, lacking relevance to osteosarcoma management and not addressing the specific treatment history and tumor characteristics effectively.